Citations

Clear

3942 citation(s) found for "To, Van".

Epidemiology of cardiogenic shock using the Shock Academic Research Consortium (SHARC) consensus definitions
Berg, David D. , Patel, Siddharth M. , Alfonso, Carlos E., Alviar, Carlos L. , Baird-Zars, Vivian M., Barsness, Gregory W. , Bennett, Courtney , Gidwani, Umesh , Goldfarb, Michael , Katz, Jason N. , Menon, Venu , Miller, Patrick, Newby, L. Kristin , Papolos, Alexander , Park, Jeong‐Gun , Pierce, Matthew J, Proudfoot, Alastair , Sridharan, Lakshmi , Thompson, Andrea D. , Goldfarb, Michael , Pierce, Matthew , Menon, Venu , Park, Jeong-Gun , van Diepen, Sean , Goldfarb, Michael , Goldfarb, Michael , Berg, David , Thompson, Andrea , Patel, Siddharth M , Pierce, Matthew J , Proudfoot, Alastair G , Bohula, Erin A. , Barnett, Christopher F. , Chaudhry, Sunit‐Preet , Fordyce, Christopher B. , Ghafghazi, Shahab , Miller, P Elliott, Sinha, Shashank S , Diepen, Sean van , Morrow, David A.

Mayo Clinic

European Heart Journal: Acute Cardiovascular Care | August 29, 2024 | Volume: 13 | Issue: 10 | Pages: 709-714

10.1093/ehjacc/zuae098 | PMID 39208447 Get It

Abstract Aims The Shock Academic Research Consortium (SHARC) recently proposed pragmatic consensus definitions to standardize classification of cardiogenic shock (CS) in registries and clinical trials. We aimed to describe contemporary CS epidemiology using the SHARC definitions in a cardiac intensive care unit (CICU) population. Methods and results The Critical Care Cardiology Trials Network (CCCTN) is a multinational research network of advanced CICUs coordinated by the TIMI Study Group (Boston, MA). Cardiogenic shock was defined as a cardiac disorder resulting in SBP < 90 mmHg for ≥30 min [or the need for vasopressors, inotropes, or mechanical circulatory support (MCS) to maintain SBP ≥ 90 mmHg] with evidence of hypoperfusion. Primary aetiologic categories included acute myocardial infarction-related CS (AMI-CS), heart failure-related CS (HF-CS), and non-myocardial (secondary) CS. Post-cardiotomy CS was not included. Heart failure-related CS was further subcategorized as de novo vs. acute-on-chronic HF-CS. Patients with both cardiogenic and non-cardiogenic components of shock were classified separately as mixed CS. Of 8974 patients meeting shock criteria (2017–23), 65% had isolated CS and 17% had mixed shock. Among patients with CS (n = 5869), 27% had AMI-CS (65% STEMI), 59% HF-CS (72% acute-on-chronic, 28% de novo), and 14% secondary CS. Patients with AMI-CS and de novo HF-CS were most likely to have had concomitant cardiac arrest (P < 0.001). Patients with AMI-CS and mixed CS were most likely to present in more severe shock stages (SCAI D or E; P < 0.001). Temporary MCS use was highest in AMI-CS (59%). In-hospital mortality was highest in mixed CS (48%), followed by AMI-CS (41%), similar in de novo HF-CS (31%) and secondary CS (31%), and lowest in acute-on-chronic HF-CS (25%; P < 0.001). Conclusion SHARC consensus definitions for CS classification can be pragmatically applied in contemporary registries and reveal discrete subpopulations of CS with distinct phenotypes and outcomes that may be relevant to clinical practice and future research.
Cancer in Patients With Incidental Asymmetric Oropharynx Positron Emission Tomography Uptake
Armstrong, Michael , O’Byrne, Thomas J., Gottlich, Harrison C. , Tasche, Kendall K. , Moore, Eric J. , Gamez, Mauricio E. , Neben-Wittich, M.A. , Price, Katharine A., Lowe, Val J. , Abel, Kathryn M. Van , O'Byrne, Thomas J, Gamez, Mauricio , Lester, Scott C. , Neben-Wittich, Michelle A, Van Abel, Kathryn M , Burkett, Brian J. , Yin, Linda X. , Price, Daniel L. , Routman, David M. , Daniel, J.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | August 29, 2024 | Volume: 150 | Issue: 12 | Pages: 1078

10.1001/jamaoto.2024.2556 | PMID 39207815 Get It

ImportanceAsymmetric oropharynx uptake on positron emission tomography (PET)/computed tomography (CT) is a common incidental finding and often prompts otolaryngology referral to rule out malignancy; however, the true risk of malignancy based on this finding is unknown.ObjectiveTo identify the incidence of oropharynx cancer in patients with incidental asymmetric oropharynx PET uptake.Design, Setting, and ParticipantsIn this retrospective cohort study, patients 18 years and older undergoing PET/CT scans at Mayo Clinic between January 2001 and December 2018 were included. Patients with a history or pretest suspicion of oropharynx cancer were excluded. Data were analyzed from March 2021 to December 2023.ExposureBlinded radiologic review of imaging studies, including measurement of maximum standardized uptake values (SUVmax) of the ipsilateral side of concern and contralateral side. Retrospective medical record review for associated clinical data.Main Outcomes and MeasuresThe primary study outcome was the incidence of oropharynx cancer diagnosis in patients with asymmetric oropharynx PET uptake. The primary outcome was formulated before data collection.ResultsOf the 1854 patients identified with asymmetric oropharynx PET uptake, 327 (17.6%) met inclusion criteria. Of these, 173 (52.9%) were male, and the median (range) age was 65.0 (24.8-90.7) years. The mean (SD) follow-up interval was 52.1 (43.4) months. A total of 18 of 327 patients (5.5%) were newly diagnosed with oropharynx cancer. The most common diagnosis was squamous cell carcinoma (n = 9), followed by lymphoma (n = 8), and sarcoma (n = 1). Patients with an incidental diagnosis of oropharynx cancer had higher mean (SD) ipsilateral SUVmax (8.7 [3.7] vs 5.3 [1.9]) and SUVmax ratio (3.0 [1.6] vs 1.6 [0.6]) compared with patients with normal examination findings. SUVmax ratio and difference were found to be good discriminators of oropharynx cancer, with areas under the receiver operating characteristic curve of 86.3% (95% CI, 76.4-94.6) and 85.8% (95% CI, 74.8-94.6), respectively. Patients with a new diagnosis of oropharynx cancer were more likely to have a corresponding CT abnormality than those with normal examination findings (6 of 18 [33%] vs 24 of 295 [8.1%]). Patients with concerning lesions on oropharynx palpation by an otolaryngology health care professional were significantly more likely to be diagnosed with oropharynx cancer compared with patients with normal examination findings (odds ratio, 28.4; 95% CI, 6.6-145.8).Conclusions and RelevanceIn this cohort study, while incidental asymmetric oropharynx PET uptake was common, a new diagnosis of oropharynx cancer was not and potentially results in a large volume of unnecessary referrals and work-up. Using SUVmax ratio, SUVmax difference, and CT correlation may increase the benefit of referral. Patients with a palpable oropharynx lesion and asymmetric oropharynx PET uptake should undergo confirmatory biopsy.
Imaging arterial and venous vessels using Iron Dextran enhanced multi‐echo 3D gradient echo MRI at 7T
Li, Yinghao , Li, Wei , Paez, Adrian , Cao, Di , Sun, Yang-bai , Gu, Chunming , Miao, Xinyuan , Li, Wenbo , Pillai, Jay J. , Earley, Christopher J. , Sun, Yuanqi , Sun, Yuanqi , Li, Xu , Hua, Jun , Pillai, Jay J , Zhang, Kaihua , Liu, Peiying , Lu, Hanzhang , Zijl, Peter C.M. van , Li, Xu

Mayo Clinic

NMR in Biomedicine | August 26, 2024 | Volume: 37 | Issue: 12 | Pages: No page available

10.1002/nbm.5251 | PMID 39187441 Get It

AbstractIron Dextran is a widely used iron oxide compound to treat iron‐deficiency anemia patients in the clinic. Similar to other iron oxide compounds such as Ferumoxytol, it can also be used off‐label as an intravascular magnetic resonance imaging (MRI) contrast agent due to its strong iron‐induced T2 and T2* shortening effects. In this study, we seek to evaluate the feasibility of using Iron Dextran enhanced multi‐echo susceptibility weighted imaging (SWI) MRI at 7T to image arterial and venous blood vessels in the human brain. Phantom experiments were performed to measure the r2* relaxivity for Iron Dextran in blood, based on which the SWI sequence was optimized. Pre‐ and post‐infusion MR images were acquired in human subjects from which maps of arteries and veins were extracted. The post‐contrast SWI images showed enhanced susceptibility difference between blood and the surrounding tissue in both arteries and veins. Our results showed that the proposed Iron Dextran enhanced multi‐echo SWI approach allowed the visualization of blood vessels with diameters down to ~100 μm, including small blood vessels supplying and draining small brain structures such as the hippocampus. We conclude that Iron Dextran can be an alternative iron‐based MRI contrast agent for blood vessel imaging in the human brain.
Lymph node staging and treatment in pediatric patients with soft tissue sarcomas: A consensus opinion from the Children’s Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe
Scheltinga, Scheila E. J. Terwisscha van, Keizer, Bart de , McCarville, M. Beth , Casey, Dana L. , Walterhouse, David , Hiemcke‐Jiwa, Laura S. , Franzius, Christiane, Vokuhl, Christian , Birz, Suzi , Rodeberg, David A. , Casey, Dana L , de Keizer, Bart , Schoot, Reineke A , Routh, Jonathan C. , Seitz, Guido , Kao, Simon C. , Shulkin, Barry L. , Ewijk, Roelof van , Allen‐Rhoades, Wendy , Mercolini, Federico , Merks, Johannes H M , Orbach, Daniel , Kapadia, Tejas , Fajardo, Raquel Dávila , Corti, Federica De , Tang, Vivian , Metts, Jonathan L. , Oberoi, Saphna , Dasgupta, Roshni

Mayo Clinic

No container title available | August 23, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.172445880.02878798/v1 Get It

Accurate staging of nodal involvement in pediatric sarcoma patients is important to determine correct systemic and local therapy, with the goal to reduce subsequent recurrences. However, differences in lymph node staging strategies, definitions, and treatment protocols between the Children’s Oncology Group (COG), European Pediatric Soft Tissue Sarcoma Study Group (EpSSG), and the Cooperative Weichteil Sarkom Studiengruppe (CWS), complicate comparisons. In this article we try to establish internationally recognized recommendations for lymph node assessment and treatment of children and adolescents diagnosed with RMS and NRSTS according to the Consensus Conference Standard Operating Procedure methodology.
PUNCH CD3-OLS: A Phase 3 Prospective Observational Cohort Study to Evaluate the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) in Adults With Recurrent Clostridioides difficile Infection
Feuerstadt, Paul , Knapple, W , Hise, Nicholas W. Van, Baggott, Brian, Guthmueller, Beth, Bancke, Lindy, Gamborg, Michael, Steiner, Theodore S. , Handel, Daniel Van, Khanna, Sahil , Khanna, S , Feuerstadt, Paul , Chopra, Teena , Dubberke, Erik R.

Mayo Clinic

Clinical Infectious Diseases | August 23, 2024 | Volume: 80 | Issue: 1 | Pages: 43-51

10.1093/cid/ciae437 | PMID 39180326 Get It

Abstract Background The aim of this study was to evaluate the safety and efficacy of fecal microbiota, live-jslm (RBL; REBYOTA)—the first single-dose, broad consortia microbiota-based live biotherapeutic approved by the US Food and Drug Administration for preventing recurrent Clostridioides difficile infection (rCDI) in adults following standard-of-care (SOC) antibiotic treatment. Methods PUNCH CD3-OLS was a prospective, phase 3, open-label study, conducted across the US and Canada. Participants were aged ≥18 years with documented rCDI and confirmed use of SOC antibiotics. Participants with comorbidities including inflammatory bowel disease and mild-to-moderate immunocompromising conditions could be enrolled. A single dose of RBL was rectally administered within 24–72 hours of antibiotic completion. The primary endpoint was the number of participants with RBL- or administration-related treatment-emergent adverse events (TEAEs). Secondary endpoints included treatment success and sustained clinical response, at 8 weeks and 6 months after RBL administration, respectively. Results Overall, 793 participants were enrolled, of whom 697 received RBL. TEAEs through 8 weeks after administration were reported by 47.3% of participants; most events were mild or moderate gastrointestinal disorders. Serious TEAEs were reported by 3.9% of participants. The treatment success rate at 8 weeks was 73.8%; in participants who achieved treatment success, the sustained clinical response rate at 6 months was 91.0%. Safety and efficacy rates were similar across demographic and baseline characteristic subgroups. Conclusions RBL was safe and efficacious in participants with rCDI and common comorbidities. This is the largest microbiota-based live biotherapeutic study to date, and findings support use of RBL to prevent rCDI in a broad patient population. Clinical Trials Registration NCT03931941.
Loss of HD-PTP function results in lipodystrophy, defective cellular signaling and altered lipid homeostasis
Schultz, Destiny F. , Davies, Brian A., Payne, Johanna A., Martin, Cole P , Minard, Annabel Y. , Childs, Bennett G. , Jeganathan, Karthik B. , Sturmlechner, Ines , White, Thomas A. , Harkema, Liesbeth , Chen, Huiqin , Davies, Michael A. , Jachim, Sarah K. , Hu, Li , Deursen, Jan M. van , Billadeau, Daniel D. , Katzmann, David J. , Jeganathan, Karthik B , Sturmlechner, Ines , de Bruin, Alain , Harkema, Liesbeth , Jachim, Sarah , LeBrasseur, Nathan K , Piper, Robert C , Baker, Darren J , van Deursen, Jan M , Billadeau, Daniel D , Katzmann, David J , Zhang, Cheng , Bruin, Alain de , LeBrasseur, Nathan K. , Piper, Robert C. , Baker, Darren J.

Mayo Clinic

Journal of Cell Science | August 19, 2024 | Volume: 137 | Issue: 18 | Pages: No page available

10.1242/jcs.262032 | PMID 39155850 Get It

ABSTRACT His domain protein tyrosine phosphatase (HD-PTP; also known as PTPN23) facilitates function of the endosomal sorting complexes required for transport (ESCRTs) during multivesicular body (MVB) formation. To uncover its role in physiological homeostasis, embryonic lethality caused by a complete lack of HD-PTP was bypassed through generation of hypomorphic mice expressing reduced protein, resulting in animals that are viable into adulthood. These mice exhibited marked lipodystrophy and decreased receptor-mediated signaling within white adipose tissue (WAT), involving multiple prominent pathways including RAS/MAPK, phosphoinositide 3-kinase (PI3K)/AKT and receptor tyrosine kinases (RTKs), such as EGFR. EGFR signaling was dissected in vitro to assess the nature of defective signaling, revealing decreased trans-autophosphorylation and downstream effector activation, despite normal EGF binding. This corresponds to decreased plasma membrane cholesterol and increased lysosomal cholesterol, likely resulting from defective endosomal maturation necessary for cholesterol trafficking and homeostasis. The ESCRT components Vps4 and Hrs have previously been implicated in cholesterol homeostasis; thus, these findings expand knowledge on which ESCRT subunits are involved in cholesterol homeostasis and highlight a non-canonical role for HD-PTP in signal regulation and adipose tissue homeostasis.
Defining the Spatial Resolution of Analyte Recovery during Microperfusion-Based Sampling of Brain Parenchyma
Stangler, Luke A, Chang, Su-Youne , Kim, Inyong , Bennet, Kevin E. , Howe, Charles L. , Choi, Jonghoon, Howe, Charles L , Choi, Jonghoon , Kouzani, Abbas Z. , Burns, Terry C. , Gompel, Jamie J. Van , Worrell, Gregory A.

Mayo Clinic

ACS Chemical Neuroscience | August 19, 2024 | Volume: 15 | Issue: 17 | Pages: 3220-3227

10.1021/acschemneuro.4c00410 | PMID 39155540 Get It

Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer
O’Regan, Ruth, Francis, Prudence A. , Kammler, Roswitha , Viale, Giuseppe, Dell’Orto, Patrizia , Láng, István, Bellet, Meritxell , Bonnefoi, Hervé , Villa, Federica , Bernardo, Antônio , Neven, Patrick , Müller, Bettina , Zaman, Khalil , Martino, Silvana, Jerzak, Katarzyna J. , Davidson, Nancy E. , Mackelenbergh, Marion van , Schnabel, Catherine A. , Treuner, Kai , Regan, Meredith M. , Ingle, James N. , Bonnefoi, Hervé R , Francis, Prudence A , Zhang, Yi , Fleming, Gini F. , Viale, G., Tondini, Carlo Alberto , Ciruelos, Eva , Karlsson, Per , Jochum, Wolfram , Geyer, Charles E. , Coleman, Robert E. , Loi, Sherene , Colleoni, Marco

Mayo Clinic

JAMA Oncology | August 15, 2024 | Volume: 10 | Issue: 10 | Pages: 1379

10.1001/jamaoncol.2024.3044 | PMID 39145953 Get It

ImportanceAdjuvant ovarian function suppression (OFS) with oral endocrine therapy improves outcomes for premenopausal patients with hormone receptor–positive (HR+) breast cancer but adds adverse effects. A genomic biomarker for selecting patients most likely to benefit from OFS-based treatment is lacking.ObjectiveTo assess the predictive and prognostic performance of the Breast Cancer Index (BCI) for OFS benefit in premenopausal women with HR+ breast cancer.Design, Setting, and ParticipantsThis prospective-retrospective translational study used all available tumor tissue samples from female patients from the Suppression of Ovarian Function Trial (SOFT). These individuals were randomized to receive 5 years of adjuvant tamoxifen alone, tamoxifen plus OFS, or exemestane plus OFS. BCI testing was performed blinded to clinical data and outcome. The a priori hypothesis was that BCI HOXB13/IL17BR ratio (BCI[H/I])–high tumors would benefit more from OFS and high BCI portended poorer prognosis in this population. Settings spanned multiple centers internationally. Participants included premenopausal female patients with HR+ early breast cancer with specimens in the International Breast Cancer Study Group tumor repository available for RNA extraction. Data were collected from December 2003 to April 2021 and were analyzed from May 2022 to October 2022.Main Outcomes and MeasuresPrimary end points were breast cancer–free interval (BCFI) for the predictive analysis and distant recurrence-free interval (DRFI) for the prognostic analyses.ResultsTumor specimens were available for 1718 of the 3047 female patients in the SOFT intention-to-treat population. The 1687 patients (98.2%) who had specimens that yielded sufficient RNA for BCI testing represented the parent trial population. The median (IQR) follow-up time was 12 (10.5-13.4) years, and 512 patients (30.3%) were younger than 40 years. Tumors were BCI(H/I)-low for 972 patients (57.6%) and BCI(H/I)-high for 715 patients (42.4%). Patients with tumors classified as BCI(H/I)-low exhibited a 12-year absolute benefit in BCFI of 11.6% from exemestane plus OFS (hazard ratio [HR], 0.48 [95% CI, 0.33-0.71]) and an absolute benefit of 7.3% from tamoxifen plus OFS (HR, 0.69 [95% CI, 0.48-0.97]) relative to tamoxifen alone. In contrast, patients with BCI(H/I)-high tumors did not benefit from either exemestane plus OFS (absolute benefit, −0.4%; HR, 1.03 [95% CI, 0.70-1.53]; P for interaction = .006) or tamoxifen plus OFS (absolute benefit, −1.2%; HR, 1.05 [95% CI, 0.72-1.54]; P for interaction = .11) compared with tamoxifen alone. BCI continuous index was significantly prognostic in the N0 subgroup for DRFI (n = 1110; P = .004), with 12-year DRFI of 95.9%, 90.8%, and 86.3% in BCI low-risk, intermediate-risk, and high-risk N0 cancers, respectively.Conclusions and RelevanceIn this prospective-retrospective translational study of patients enrolled in SOFT, BCI was confirmed as prognostic in premenopausal women with HR+ breast cancer. The benefit from OFS-containing adjuvant endocrine therapy was greater for patients with BCI(H/I)-low tumors than BCI(H/I)-high tumors. BCI(H/I)-low status may identify premenopausal patients who are likely to benefit from this more intensive endocrine therapy.